FDA
-
-
-
-
-
-
-
INmune Bio gets MHRA alignment for 2026 UK drug application
-
-
-
-
-
-
-
INmune Bio publishes Phase 2 Alzheimer's trial results in peer-reviewed journal
-
-
-
-
-
-
-
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
-
-
-
-
-
-
-
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
-
-
-
-
-
-
-
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
-
-
-
-
-
-
-
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
-
-
-
-
-
-
-
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
-
325,536 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

